Home | FAQs | About Us | Partner With Us | In the News | Related Links | Contact Us | Campaign Materials

---

Email Updates

Print Page

Email Page

Send an E-Card

Link to Us

Widgets

5/24/2010

A Maryland firm is in the third phase of testing an experimental vaccine which, unlike a nicotine step-down or replacement product, stimulates a body’s resistance to nicotine. The vaccine triggers the production of antibodies that then cling to the nicotine molecule, thereby making it too big to cross the blood-brain barrier, where it would trigger an addictive rush.